ANI Pharmaceuticals, Inc.(ANIP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ANIP ANI Pharmaceuticals, Inc.

未开盘 05-08 16:00:00 EDT

81.86

-2.05

-2.44%

盘后82.20

+0.34+0.42%

16:47 EDT

最高87.76	最低79.37	成交量130.77万
今开87.76	昨收83.91	日振幅10.00%
总市值18.63亿	流通市值17.09亿	总股本2,276万
成交额1.10亿	换手率6.26%	流通股本2,088万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ANIP","market":"US","secType":"STK","nameCN":"ANI Pharmaceuticals, Inc.","latestPrice":81.86,"timestamp":1778270400000,"preClose":83.91,"halted":0,"volume":1307703,"hourTrading":{"tag":"盘后","latestPrice":82.2,"preClose":81.86,"latestTime":"16:47 EDT","volume":101428,"amount":8306305.13,"timestamp":1778273248527,"change":0.34,"changeRate":0.004153,"amplitude":0.004153},"delay":0,"changeRate":-0.024430937909665086,"floatShares":20878000,"shares":22761062,"eps":3.902954,"marketStatus":"未开盘","change":-2.05,"latestTime":"05-08 16:00:00 EDT","open":87.76,"high":87.76,"low":79.3666,"amount":109920231.05988,"amplitude":0.100029,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.902954,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778486400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1064980800000,"exchange":"NASDAQ","adjPreClose":83.91,"preHourTrading":{"tag":"盘前","latestPrice":87.76,"preClose":83.91,"latestTime":"09:29 EDT","volume":7696,"amount":680844.463936,"timestamp":1778246999999,"change":3.85,"changeRate":0.045882,"amplitude":0.079847},"postHourTrading":{"tag":"盘后","latestPrice":82.2,"preClose":81.86,"latestTime":"16:47 EDT","volume":101428,"amount":8306305.13,"timestamp":1778273248527,"change":0.34,"changeRate":0.004153,"amplitude":0.004153},"volumeRatio":4.064280995671068,"impliedVol":0.3266,"impliedVolPercentile":0.072},"requestUrl":"/m/hq/s/ANIP/wiki","defaultTab":"wiki","newsList":[{"id":"1158845072","title":"财报前瞻｜ANI Pharmaceuticals, Inc.本季度营收预计小幅增长，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1158845072","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158845072?lang=zh_cn&edition=full","pubTime":"2026-05-01 08:50","pubTimestamp":1777596613,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals, Inc.将于2026年05月08日发布财报，市场关注本季度收入韧性与盈利波动。基于一致预期，本季度ANI Pharmaceuticals, Inc.收入预计为2.08亿美元，同比增14.88%；预计毛利率暂无一致口径；预计归母净利润或净利率暂无一致口径；预计调整后每股收益为1.31美元，同比降5.63%。近期围绕ANI Pharmaceuticals, Inc.的机构观点以谨慎为主，核心分歧集中在收入维持两位数增长与费用端扩大之间的平衡。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜ANI Pharmaceuticals, Inc.本季度营收预计小幅增长，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114075587","title":"ANI Pharmaceuticals获FDA批准上市匹莫齐特片剂 享有180天竞争性仿制药专营权","url":"https://stock-news.laohu8.com/highlight/detail?id=1114075587","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114075587?lang=zh_cn&edition=full","pubTime":"2026-04-20 18:50","pubTimestamp":1776682247,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals, Inc.近日宣布，其研发的匹莫齐特片剂已获得美国食品药品监督管理局的正式批准，并即将投入市场。值得关注的是，该药品将享有为期180天的竞争性仿制药专营权。此次获批的匹莫齐特片剂主要用于治疗图雷特综合征等运动障碍性疾病。180天的CGT专营权意味着，在此期间FDA将不会批准其他仿制药企业生产的相同剂型和规格的匹莫齐特产品上市，这为ANI Pharmaceuticals提供了重要的市场先发优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP","LU0566484027.USD","LU1559883803.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195330735","title":"ANI Pharmaceuticals公布2025年第四季度及全年创纪录财报，并重申2026年财务指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1195330735","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195330735?lang=zh_cn&edition=full","pubTime":"2026-02-27 19:50","pubTimestamp":1772193019,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals, Inc. (ANIP) 宣布其2025年第四季度及全年的财务业绩达到历史新高，展现出强劲的增长势头。同时，公司管理层对2026年的财务前景保持信心，并重申了既定的业绩目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","LU1559883803.SGD","BK4007","ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181476459","title":"财报前瞻｜ANI Pharmaceuticals, Inc.本季度营收预计增32.03%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1181476459","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181476459?lang=zh_cn&edition=full","pubTime":"2026-02-20 10:34","pubTimestamp":1771554877,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals, Inc.将于2026年02月27日发布最新财报，市场聚焦营收与盈利能否延续上行势头。上一季度，ANI Pharmaceuticals, Inc.实现营收2.28亿美元，同比增长53.58%；毛利率为59.01%；归属于母公司股东的净利润为2,661.70万美元，净利率11.68%；调整后每股收益为2.04美元，同比增长52.24%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜ANI Pharmaceuticals, Inc.本季度营收预计增32.03%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147881213","title":"修正：ANI制药第四季度Cortrophin Gel收入达1.114亿美元（非公司总收入）","url":"https://stock-news.laohu8.com/highlight/detail?id=1147881213","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147881213?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:19","pubTimestamp":1768220374,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals, Inc.最新披露的财报数据显示，其旗下产品Cortrophin Gel在第四季度表现强劲，单季度营收达到1.114亿美元。需要特别说明的是，该数字仅为Cortrophin Gel这一产品的收入，并非公司整体第四季度的总营收。\n此前市场对该公司第四季度营收的预估已被移除，此次修正进一步明确了细分产品的财务贡献。Cortrophin Gel作为公司的重要产品线，其收入表现对投资者评估业务聚焦点和增长动能具有重要参考价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4007","LU0566484027.USD","ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157372926","title":"ANI Pharmaceuticals 第三季度调整后每股收益 USD 2.04 超过 IBES 预期 USD 1.75","url":"https://stock-news.laohu8.com/highlight/detail?id=1157372926","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157372926?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572112,"startTime":"0","endTime":"0","summary":"11月7日（路透社） - ANI Pharmaceuticals 第三季度每股收益 USD 1.13。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","ANIP","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584101426","title":"Ani Pharmaceuticals, Inc.2025财年第三财季实现净利润24.13百万美元，同比增加199.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584101426","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584101426?lang=zh_cn&edition=full","pubTime":"2025-11-17 00:00","pubTimestamp":1763308813,"startTime":"0","endTime":"0","summary":"11月17日，Ani Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第三财季净利润为24.13百万美元，同比增加199.83%；其中营业收入为2.28亿美元，同比增加54.05%，每股基本收益为1.19美元。从资产负债表来看，Ani Pharmaceuticals, Inc.总负债9.02亿美元，其中短期债务15.24百万美元，资产负债比为1.57，流动比率为2.58。机构评级：截至2025年11月17日，当前有8家机构对Ani Pharmaceuticals, Inc.目标价做出预测，其中目标均价为109.88美元，其中最低目标价为90.00美元，最高目标价为121.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000026a4a5a8ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000026a4a5a8ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0566484027.USD","ANIP","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517948685","title":"Guggenheim：维持ANI Pharmaceuticals(ANIP.US)评级，由买入调整至买入评级, 目标价由84.00美元调整至86.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948685","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517948685?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:43","pubTimestamp":1741185815,"startTime":"0","endTime":"0","summary":"Guggenheim：维持ANI Pharmaceuticals(ANIP.US)评级，由买入调整至买入评级, 目标价由84.00美元调整至86.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05224348547985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193043680","title":"异动解读 | 财报业绩超预期,ANI制药盘中大涨14.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193043680","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193043680?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:45","pubTimestamp":1740753917,"startTime":"0","endTime":"0","summary":"ANI制药公司(ANIP)今日盘中股价大涨14.73%,成为市场关注的焦点。\n\n公司此前发布的2024年第四季度财报显示,其调整后每股收益为1.63美元,高于分析师普遍预期的1.44美元;营收达到1.9057亿美元,同样超出1.7537亿美元的预期水平。主因是公司两款罕见病药物Iluvien和Yutiq销售表现亮眼。\n\n另外,公司预计2025年全年调整后每股收益将达到6.12-6.49美元的区间,高于当前市场预期5.56美元的水平。在此业绩表现支撑下,安纳吉资本给予ANI股票\"买入\"评级,12个月目标价中位数达到80美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151632074","title":"ANI制药公司预计2025年调整后每股收益为6.12美元至6.49美元，而市场预期为5.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151632074","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151632074?lang=zh_cn&edition=full","pubTime":"2025-02-28 20:04","pubTimestamp":1740744262,"startTime":"0","endTime":"0","summary":"ANI制药公司预计，2025年调整后每股收益将在6.12美元至6.49美元之间，而市场预期为5.56美元。以上内容来自Benzinga Earnings专栏，原文如下：ANI Pharmaceuticals Expects 2025 Adjusted EPS Of $6.12-$6.49 Versus Consensus Of $5.56","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156054280","title":"异动解读 | 公司财报超预期,ANIP制药股盘前大涨8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156054280","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156054280?lang=zh_cn&edition=full","pubTime":"2025-02-28 19:56","pubTimestamp":1740743778,"startTime":"0","endTime":"0","summary":"周五盘前交易中,ANIP制药公司(NASDAQ:ANIP)股价大涨8.08%,引起了市场广泛关注。这一大涨很可能是由于公司2024年第四季度财报表现优异所致。\n\n根据最新财报显示,ANIP第四季度调整后每股收益为1.63美元,超过分析师平均预期的1.44美元,同比增长63%。公司第四季度销售额达到1.9057亿美元,也超出分析师预期的1.7537亿美元,同比增长44.75%。\n\n财报表现出色使市场对ANIP制药公司未来发展前景更加看好,成为当前公司股价大涨的主要驱动力。不过该公司下一季度和全年的表现还有待进一步关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113236856","title":"ANI制药公司2024年第四季度调整后每股收益$1.63 超过预期的$1.44，销售额$1.9057亿超过预期的$1.7537亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1113236856","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113236856?lang=zh_cn&edition=full","pubTime":"2025-02-28 19:54","pubTimestamp":1740743662,"startTime":"0","endTime":"0","summary":"公司报告季度销售额为$1.9057亿，超过分析师一致预期的$1.7537亿，超出预期8.67%。这比去年同期的销售额$1.3165亿增长了44.75%。以上内容来自Benzinga Earnings专栏，原文如下：ANI Pharmaceuticals  reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.44 by 13.19 percent. This is a 63 percent increase over earnings of $1.00 per share from the same period last year.  The company reported quarterly sales of $190.57 million which beat the analyst consensus estimate of $175.37 million by 8.67 percent.  This is a 44.75 percent i","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ANI制药公司2024年第四季度调整后每股收益$1.63 超过预期的$1.44，销售额$1.9057亿超过预期的$1.7537亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503626317","title":"Ani Pharmaceuticals, Inc.盘中异动 大幅拉升5.00%报56.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503626317","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503626317?lang=zh_cn&edition=full","pubTime":"2025-01-15 23:38","pubTimestamp":1736955510,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日23时38分，Ani Pharmaceuticals, Inc.股票出现异动，股价急速上涨5.00%。截至发稿，该股报56.87美元/股，成交量3.5874万股，换手率0.17%，振幅3.82%。Ani Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.53%。其相关个股中，Cbdmd, Inc.、Therapeuticsmd, Inc.、Journey Medical Corporation涨幅较大，Cbdmd, Inc.、大自然药业、Akanda Corp.较为活跃，换手率分别为58.79%、18.72%、4.77%，振幅较大的相关个股有Cbdmd, Inc.、Talphera, Inc.、Petros Pharmaceuticals, Inc.，振幅分别为28.40%、11.88%、10.50%。Ani Pharmaceuticals, Inc.公司简介：ANI Pharmaceuticals Inc 开发、制造和销售仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152338309604c655&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152338309604c655&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ANIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193537946","title":"异动解读 | ANI制药业绩超预期 股价盘前大涨8.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193537946","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193537946?lang=zh_cn&edition=full","pubTime":"2024-11-09 00:24","pubTimestamp":1731083090,"startTime":"0","endTime":"0","summary":"在2024年11月8日盘前交易中,ANI Pharmaceuticals股价大涨8.77%,引发市场广泛关注。导致该公司股价大涨的主要原因是其第三季度财报数据超出华尔街分析师预期。具体来看,ANI制药在截至2024年9月30日的第三季度公布了亮眼的财务业绩。营收方面,ANI公司季度营收为1.4833亿美元,同比增长12.5%,也超出了分析师预期的1.4435亿美元。ANI制药优异的季度业绩受到了分析师界的积极评价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ANIP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anipharmaceuticals.com","stockEarnings":[{"period":"1week","weight":0.0183},{"period":"1month","weight":0.0361},{"period":"3month","weight":0.0002},{"period":"6month","weight":-0.0948},{"period":"1year","weight":0.1444},{"period":"ytd","weight":0.037}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ANI Pharmaceuticals, Inc.于2001年4月成立于特拉华州。该公司是一家综合性的特种制药公司，致力于通过开发，制造和销售高质量的品牌和通用处方药来为公司的客户提供价值。 该公司专注于利基和高入口机会，包括受控物质，抗癌（溶瘤药），激素和类固醇，以及复杂的制剂。 该公司位于明尼苏达州Baudette的两家制药厂能够生产口服固体剂量产品，以及液体和局部，受控物质和必须在完全封闭的环境中制造的有效产品。 该公司的战略是使用其资产开发，收购，制造和销售品牌和通用专业处方药。","yearOnYearQuotes":[{"month":1,"riseRate":0.692308,"avgChangeRate":0.063441},{"month":2,"riseRate":0.423077,"avgChangeRate":0.01095},{"month":3,"riseRate":0.423077,"avgChangeRate":-0.02235},{"month":4,"riseRate":0.576923,"avgChangeRate":0.130801},{"month":5,"riseRate":0.423077,"avgChangeRate":-0.02324},{"month":6,"riseRate":0.653846,"avgChangeRate":0.039424},{"month":7,"riseRate":0.423077,"avgChangeRate":-0.036377},{"month":8,"riseRate":0.461538,"avgChangeRate":0.008153},{"month":9,"riseRate":0.423077,"avgChangeRate":0.022238},{"month":10,"riseRate":0.461538,"avgChangeRate":-0.034116},{"month":11,"riseRate":0.576923,"avgChangeRate":0.07966},{"month":12,"riseRate":0.423077,"avgChangeRate":-0.053783}],"exchange":"NASDAQ","name":"ANI Pharmaceuticals, Inc.","nameEN":"ANI Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ANI Pharmaceuticals, Inc.(ANIP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ANI Pharmaceuticals, Inc.(ANIP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ANI Pharmaceuticals, Inc.,ANIP,ANI Pharmaceuticals, Inc.股票,ANI Pharmaceuticals, Inc.股票老虎,ANI Pharmaceuticals, Inc.股票老虎国际,ANI Pharmaceuticals, Inc.行情,ANI Pharmaceuticals, Inc.股票行情,ANI Pharmaceuticals, Inc.股价,ANI Pharmaceuticals, Inc.股市,ANI Pharmaceuticals, Inc.股票价格,ANI Pharmaceuticals, Inc.股票交易,ANI Pharmaceuticals, Inc.股票购买,ANI Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ANI Pharmaceuticals, Inc.(ANIP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ANI Pharmaceuticals, Inc.(ANIP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}